1. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition
- Author
-
Takeo Sugiyama, Vincent C. Manganiello, Kasumi Shimizu, Taku Murata, Motoshi Narita, Toshiro Tagawa, and Toshiyuki Nakagawa
- Subjects
musculoskeletal diseases ,Cancer Research ,medicine.medical_specialty ,Phosphodiesterase Inhibitors ,Antineoplastic Agents ,Bone Neoplasms ,chemistry.chemical_compound ,Cell Line, Tumor ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,RNA, Neoplasm ,Pharmacology ,Osteosarcoma ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,Cell growth ,Parathyroid hormone receptor ,medicine.disease ,Cyclic Nucleotide Phosphodiesterases, Type 4 ,Isoenzymes ,Endocrinology ,Oncology ,chemistry ,3',5'-Cyclic-AMP Phosphodiesterases ,Cell culture ,biology.protein ,Cancer research ,Osteocalcin ,Alkaline phosphatase ,Osteonectin ,Growth inhibition ,Rolipram ,Cell Division - Abstract
Reverse transcription-polymerase chain reaction (RT-PCR) analysis revealed that HOSM-1 cells, an osteosarcoma cell line established from human mandible, expressed mRNA for osteoblastic markers, such as alkaline phosphatase, osteonectin, osteocalcin and parathyroid hormone receptor, thus exhibiting an osteoblastic phenotype. We have investigated a possible role of cyclic nucleotide phosphodiesterases (PDEs) in osteosarcoma cells. RT-PCR analysis revealed that HOSM-1 cells expressed mRNA for PDE4A, 4B and 4C. In addition, rolipram, a specific inhibitor of PDE4, inhibited HOSM-1 cell proliferation. The finding that PDE4 is involved in proliferation of osteosarcoma cells suggests the possibility that PDE4 may be a new target for antitumor therapy.
- Published
- 2003